A clinical overview of the Betaxolol shortage for providers: affected formulations, therapeutic alternatives, and patient management strategies.
The ongoing Betaxolol shortage is creating challenges for providers across multiple specialties. Patients are presenting with unfilled prescriptions, and the timeline for full supply restoration remains uncertain. This guide provides a clinical overview of the current situation and evidence-based guidance for managing affected patients.
| Product | Status | Details |
|---|---|---|
| Kerlone (brand oral tablets) | Permanently discontinued | Discontinued in U.S. market; no plans for return |
| Betaxolol generic tablets (10 mg, 20 mg) | Limited supply | Epic Pharma discontinued production; few manufacturers remain |
| Betoptic S (0.25% ophthalmic suspension) | Permanently discontinued | Novartis discontinued globally in 2024 |
| Betaxolol 0.5% ophthalmic solution (generic) | Limited supply | Available from select manufacturers; intermittent shortages |
The Betaxolol shortage reflects a broader pattern affecting older, low-volume generic medications. Key contributing factors include:
Betaxolol is a selective beta-1 adrenergic blocker with high lipophilicity and a long half-life (~14-22 hours), allowing once-daily dosing. When transitioning patients to alternatives, consider the following:
There are no universally accepted dose-equivalence tables for beta-blockers. However, the following approximate conversions from Betaxolol 20 mg daily can guide clinical decision-making:
Critical reminder: Betaxolol should be tapered over 1-2 weeks before discontinuation. Abrupt withdrawal may precipitate rebound tachycardia, hypertensive crisis, or myocardial ischemia—particularly in patients with underlying coronary artery disease.
Betaxolol's beta-1 selectivity gave it a distinct clinical niche: patients with concurrent reactive airway disease (asthma, COPD) who needed a topical beta-blocker for intraocular pressure (IOP) reduction. The loss of this option requires careful alternative selection.
For patients previously on Betaxolol due to respiratory concerns: Avoid switching to Timolol. Prostaglandin analogs (Latanoprost) or Brimonidine are preferred alternatives that avoid bronchospastic risk.
Patients affected by the Betaxolol shortage may experience anxiety about medication changes. Consider these communication strategies:
MedFinder for Providers can help you and your staff quickly identify pharmacies with Betaxolol in stock, reducing patient callbacks and phone tag. You can also direct patients to MedFinder to search on their own.
For more on helping patients navigate availability issues, see our guide on how to help your patients find Betaxolol in stock.
The Betaxolol shortage requires proactive patient management. For oral use, Bisoprolol and Metoprolol succinate are the strongest alternatives. For ophthalmic use, the choice depends on the patient's respiratory status—Timolol for those without airway disease, and prostaglandin analogs or Brimonidine for those with asthma or COPD. Early communication and scheduled transitions will minimize treatment gaps and patient anxiety.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
